Literature DB >> 11726573

Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.

T Eldar-Geva1, I M Spitz, N P Groome, E J Margalioth, R Homburg.   

Abstract

BACKGROUND: Activin promotes ovarian follicular development, inhibits androgen production and increases FSH and insulin secretion. Follistatin, an activin-binding protein, neutralizes activin bioactivity. Therefore, a decrease in the ratio of activin/follistatin might encourage characteristic features of polycystic ovary syndrome (PCOS). We investigated whether women with PCOS showed disordered follistatin and/or activin serum concentrations.
METHODS: The study group included 24 obese and 20 non-obese (body mass index vertical line and <27 kg/m2 respectively) clomiphene-failure PCOS patients. The control group included 16 obese and 46 non-obese patients with normal ovulatory cycles. Blood samples were obtained from the patients on day 3-5 of a progesterone-induced or spontaneous cycle and were assayed for LH, FSH, testosterone, 17-hydroxy-progesterone, androstenedione, follistatin, activin A, fasting glucose and insulin.
RESULTS: Follistatin concentrations were comparable between obese and non-obese PCOS patients (mean +/- SE; 1171 +/- 103 and 1045 +/- 159 pg/ml respectively) and significantly higher than their respective controls (628 +/- 61 and 592 +/- 49 pg/ml, P < 0.0001 and P < 0.02 respectively). Activin A concentrations were comparable between the four groups (590 +/- 35, 513 +/- 74, 661 +/- 87 and 595 +/- 43 pg/ml in obese and non-obese PCOS and controls respectively). Stepwise regression analyses for relationships between follistatin or activin A levels and all other variables indicated that follistatin was significantly and independently positively affected by PCOS (P < 0.0001), age (P < 0.02), androstenedione (P < 0.03) and weight (P < 0.05). Activin A was significantly and independently negatively affected by PCOS (P < 0.003) and FSH (P < 0.03), and positively affected by weight (P < 0.009) and androstenedione (P < 0.02).
CONCLUSIONS: Serum follistatin is increased in PCOS patients, regardless of obesity. PCOS is the most significant variable that relates to high follistatin and low activin A serum concentration. A high follistatin/activin ratio could well contribute to the pathophysiology of PCOS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726573     DOI: 10.1093/humrep/16.12.2552

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  24 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors.

Authors:  Sivan Vadakkadath Meethal; Tianbing Liu; Hsien W Chan; Erika Ginsburg; Andrea C Wilson; Danielle N Gray; Richard L Bowen; Barbara K Vonderhaar; Craig S Atwood
Journal:  J Neurochem       Date:  2009-05-29       Impact factor: 5.372

3.  Alteration in follistatin gene expression detected in prenatally androgenized rats.

Authors:  Marziyeh Salehi Jahromi; Fahimeh Ramezani Tehrani; Jennifer W Hill; Mahsa Noroozzadeh; Maryam Zarkesh; Asghar Ghasemi; Azita Zadeh-Vakili
Journal:  Gynecol Endocrinol       Date:  2017-02-26       Impact factor: 2.260

4.  Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome.

Authors:  Yanqiu Xia; Pei Zhao; Hongli Huang; Yuan Xie; Rong Lu; Li Dong
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

5.  Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function.

Authors:  Nikolaos Perakakis; Jagriti Upadhyay; Wael Ghaly; Joyce Chen; Pavlina Chrysafi; Athanasios D Anastasilakis; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-05-09       Impact factor: 8.694

Review 6.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

7.  Gonadal soma controls ovarian follicle proliferation through Gsdf in zebrafish.

Authors:  Yi-Lin Yan; Thomas Desvignes; Ruth Bremiller; Catherine Wilson; Danielle Dillon; Samantha High; Bruce Draper; Charles Loren Buck; John Postlethwait
Journal:  Dev Dyn       Date:  2017-09-25       Impact factor: 3.780

Review 8.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

Review 9.  Polycystic ovary syndrome and its developmental origins.

Authors:  Daniel A Dumesic; David H Abbott; Vasantha Padmanabhan
Journal:  Rev Endocr Metab Disord       Date:  2007-06       Impact factor: 6.514

10.  Role of follistatin in promoting adipogenesis in women.

Authors:  John N Flanagan; Kristina Linder; Niklas Mejhert; Elisabeth Dungner; Kerstin Wahlen; Pauline Decaunes; Mikael Rydén; Peyman Björklund; Stefan Arver; Shalender Bhasin; Anne Bouloumie; Peter Arner; Ingrid Dahlman
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.